Morningstar

Gilead Sciences Inc GILD

Morningstar Rating
Unlock
Stock XNAS Rating as of
$83.61 +0.57 (0.69%)
View Full Chart
As of Delayed Price Closed

Company Report

View Archive

Gilead's Long-Term Dominance of the HIV Treatment and Prevention Markets Supports a Wide Moat

Karen Andersen

Gilead Sciences generates stellar profit margins with its HIV and hepatitis C virus, or HCV, portfolio, which requires only a small salesforce and inexpensive manufacturing. We think its portfolio and pipeline support a wide moat, but Gilead needs HCV market stabilization, strong continued innovation in HIV, solid oncology pipeline data, and smart future acquisitions to return to growth.

Read Full Report

Price vs Fair Value

View History
GILD is trading at a 291% premium.
Price
$83.61
Fair Value
$75.00
Uncertainty
Medium
1-Star Price
$356.88
5-Star Price
$84.10
Economic Moat
Kgnsh
Capital Allocation
Jtwrdmcg

Bulls Say, Bears Say

Bulls

Gilead markets several single-tablet regimens for HIV, and its next-generation products with better long-term safety profiles, led by Biktarvy, are boosting the company's market share.

Bears

Biktarvy's success creates a patent cliff in 2033, and it could be difficult to improve on this daily HIV drug regimen.

Show More

News

View All

Trading Information

Previous Close Price
$83.04
Day Range
$83.04–84.33
52-Week Range
$62.07–87.87
Bid/Ask
$83.45 / $84.28
Market Cap
$104.09 Bil
Volume/Avg
5.5 Mil / 6.6 Mil

Key Statistics

Price/Earnings (Normalized)
17.83
Price/Sales
3.76
Dividend Yield (Trailing)
3.66%
Dividend Yield (Forward)
3.68%
Total Yield
4.32%

Company Profile

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Sector
Healthcare
Industry
Drug Manufacturers - General
Stock Style Box
Large Value
Total Number of Employees
18,000
Website
https://www.gilead.com

Competitors

Valuation

View More
Metric
GILD
MRK
ABBV
Price/Earnings (Normalized)
 17.8317.4618.20
Price/Book Value
 5.706.6150.75
Price/Sales
 3.764.646.28
Price/Cash Flow
 9.0515.4518.48
Price/Earnings
GILD
MRK
ABBV

Financial Strength

Metric
GILD
MRK
ABBV
Quick Ratio
 0.690.880.59
Current Ratio
 1.141.470.81
Interest Coverage
 2.5813.073.51
Quick Ratio
GILD
MRK
ABBV

Profitability

Metric
GILD
MRK
ABBV
Return on Assets (Normalized)
 9.97%15.46%13.66%
Return on Equity (Normalized)
 28.96%41.15%189.99%
Return on Invested Capital (Normalized)
 14.56%22.92%27.06%
Return on Assets
GILD
MRK
ABBV

Drug Manufacturers - General Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Eli Lilly and Co
LLY
VfwylrlvglGtgb$790.4 Bil
 Johnson & Johnson
JNJ
KsbxjyyzgPnjj$388.5 Bil
 AbbVie Inc
ABBV
KcdxfjppNvh$344.1 Bil
 Merck & Co Inc
MRK
XlcsrkdxYng$288.2 Bil
 Roche Holding AG ADR
RHHBY
TblylftjfJkghn$258.7 Bil
 AstraZeneca PLC ADR
AZN
WwwhqftxnLqcvk$242.3 Bil
 Novartis AG ADR
NVS
NjjfqfqlHzwl$234.2 Bil
 Amgen Inc
AMGN
BdwjdzvtSdx$173.4 Bil
 Pfizer Inc
PFE
SztxmxhShwt$164.8 Bil
 Sanofi SA ADR
SNY
TfqkmrsxMctdr$144.3 Bil

Sponsor Center